Kornimate/medical-research-clean huggingface dataset:
evaluation of an innovative speech-enabled translator in emergency settings

Conditions: Diagnoses Disease

Summary: survey-based satisfaction, performance and technical features evaluation of a speech-enabled fixed-phrase translation tool (babeldr) in an emergency department.


Eligibility criteria:
inclusion criteria: * as per inclusion criteria, patients were required to have no understanding of french, thus making a diagnostic interview by the doctors impossible. exclusion criteria: * exclusion criteria concerned patients who shared a common language with the doctor and/or were not able to read in their native language.

Keywords: translation tool anamnesis
effect of incentive integrated e-ibd chronic disease management model on the quality of life in ibd patients

Conditions: Inflammatory Bowel Diseases; Crohn Disease; Ulcerative Colitis

Summary: this study aims to prospectively explore the effect of incentive-integrated e-ibd (electronic inflammatory bowel disease) chronic disease management model on the improvement of ibd quality of life, and provide a more effective chronic disease management model for improving the quality of life and social participation of ibd patients.the investigators firstly identify the ibd patients in need of empowerment disease activities through the questionnaire .then, the investigators feedback the patients' education content according to their needs found.based on the social support network of patient organization and the medical support network of tertiary medical institutions, the investigators complete the empowerment process of ibd patients' self-management initiative and self-management ability, through the internet. finally ,the investigators evaluate the quality of life(qol), social participation,disease self-management level via questionnaire . the primary outcome is the improvement of qol score after three months' intervention.


Eligibility criteria:
inclusion criteria: * 1.clinically diagnosed ibd patients,according to the criteria of the inflammatory bowel group of the gastroenterology branch of the chinese medical association in 2018; * 2.aged 18 to 75 years old; * 3.understand and comply with the requirements of the program and sign informed consent. * 4.identified as need intervention according to the patient identification questionnaire screening; * 5.patients with the ability to complete all course training and/or follow-up work; * 6.enrolled at least one year ahead of end of this study(for garantee of enough folllow-up time). exclusion criteria: * 1.unable or unwilling to sign the consent form, or unable to follow the research procedure; * 2.patients who have had a stoma or ileorectal anastomosis (partial scales are not available); * 3.patients who do not complete training on time or do not complete follow-up assessments in their entirety; * 4.patients with other malignancies or life-threatening complications； * 5.pregnancy or lactation； * 6.patients whose remaining follow-up time less than one year before the end of this study.
evaluation of the benefit of antiviral treatment with valganciclovir on congenital cmv infection-related deafness on hearing and balance

Conditions: Congenital Cytomegalovirus (CMV)

Summary: congenital cytomegalovirus (cmv) infection is the leading cause of non-genetic neurosensory deafness and affects 0.5 to 1% of births. twenty to thirty per cent of children will develop deafness, some of whom will progress gradually to profound bilateral deafness. no curative treatment is currently offered for this deterioration in hearing and management involves the use of a hearing aid or cochlear implant. many studies describe the utility of antiviral treatment on the course of the deafness. these mostly involve neonates with multi-system symptomatic forms of the infection who have been given 6 weeks of ganciclovir possibly switched to valganciclovir, which has shown benefit in stabilising auditory loss, or even improvement.

congenital cytomegalovirus (cmv) infection is the leading cause of non-genetic neurosensory deafness and affects 0.5 to 1% of births. twenty to thirty per cent of children will develop deafness, some of whom will progress gradually to profound bilateral deafness. no curative treatment is currently offered for this deterioration in hearing and management involves the use of a hearing aid or cochlear implant. many studies describe the utility of antiviral treatment on the course of the deafness. these mostly involve neonates with multi-system symptomatic forms of the infection who have been given 6 weeks of ganciclovir possibly switched to valganciclovir, which has shown benefit in stabilising auditory loss, or even improvement.

Eligibility criteria:
inclusion criteria: * children ≥ 6 months old and \< 12 years old * past history of proven congenital cmv infection * auditory threshold of between 40 and 90 db in at least 1 ear. exclusion criteria: * bilateral deafness \> 90 db * contraindication to valganciclovir, particularly: neutropenia with a known neutrophil count of \<500/mm3, hb\<8g/dl or platelets\< 25,000/mm3 (fbc to be confirmed before randomisation) * past history of neutropenia on valganciclovir or allergy to the compound * renal impairment with creatinine clearance of \< 10 ml/min/1.72m2 (confirmation of renal function before randomisation) according to the schwartz equation * patients on other antiviral treatment * gastrointestinal absorption problems * patients participating in a biomedical research project on a medicinal product or similar product
chronic ankle instability return to sport

Conditions: Chronic Ankle Instability

Summary: real-life, observational, monocentric, prospective, longitudinal study, carried out at the european center for sports rehabilitation (cers), france.

the data will be collected through an electronic case report form completed by the physician, and some auto-questionnaire completed by the patient.

Eligibility criteria:
inclusion criteria: * age ≥ 15 years; * patient treated at the european sports rehabilitation center after a first arthroscopic surgery on the external lateral ligament of the ankle for chronic instability by anatomical reconstruction: * with tendon graft; * by suture with biological reinforcement; * non-opposition of the patient and his/her parents (if minor) to the collection of his/her personal data. exclusion criteria: - minor patient (age \<18 years) not accompanied by one of his/her parents or legal representative during the inclusion visit; * history of surgery on the same ankle; * associated complex osteochondral or internal ligament damage, syndesmosis, fracture; * non-anatomical reconstruction; * inability of the patient to understand the study protocol; * vulnerable person whose inclusion is not justified by the purposes of the research: pregnant woman, person undergoing psychiatric care, or adult person subject to legal protection.
environmental exposure and neurological diseases questionnaire

Conditions: Amyotrophic Lateral Sclerosis

Summary: the proposed research is particularly relevant to the national als registry and public environmental health issues because it addresses the potential environmental causes of sporadic als. the research will develop an als surveillance program in ohio that can be compared with the national and state-metro surveillance programs of the national als registry, and novel methodologies to determine the role of the cyanobacterial toxin, bmaa (beta-methylamino-l-alanine), and other environmental toxins/toxicants as risk factors for als. this work will advance the mission of the centers for disease control agency for toxic substances and disease registry (cdc atsdr) national als registry by offering data on als cases in ohio that address public health concerns over the effects of chronic exposure to cyanobacterial blooms in lake erie.


Eligibility criteria:
inclusion criteria: * als * non-neurodegenerative controls * can willingly give consent * over 18 years of age exclusion criteria: * cannot give consent * under 18 years of age
bleeding pattern study

Conditions: Oral Contraceptive

Summary: the aim of this study is to evaluate bleeding pattern, cycle control, contraceptive efficacy and safety of this oral contraceptive in two different regimens of intake.

the study has previously been posted by schering ag, germany. schering ag, germany has been renamed to bayer schering pharma ag, germany. bayer schering pharma ag, germany is the sponsor of the trial.

Eligibility criteria:
inclusion criteria: * healthy female volunteers aged between 18 and 40 years requiring contraception. exclusion criteria: * pregnancy or lactation. * any conditions that might interfere with the outcome as well as all contraindications for oc use.

Keywords: contraception, bleeding pattern
dynamic light scattering and keratoscopy for corneal examination

Conditions: Corneal Diseases

Summary: this pilot study will examine the usefulness of a new instrument called the dynamic light scattering (dls) device for documenting and monitoring changes in the cornea, the front part of the eye where contact lenses are placed. the dls device uses a low-intensity laser similar to that used in supermarket checkouts to measure the cloudiness of the cornea. the results of this study may lead to further investigations using dls to discover the cause of corneal clouding and to develop treatments to prevent it. healthy volunteers and patients with corneal clouding or opacification 18 years of age and older may be eligible for this study. participants will have a standard eye examination, including a check of visual acuity and eye pressure. the retina will also be examined and photographs of the cornea may be taken. for the dls test, the subject sits in front of the device and looks at a yellow-green target while the cloudiness of the cornea is measured. subjects will be tested four times. the entire procedure takes less than 30 minutes.

corneal disease and injuries are the leading cause of visits to eye care clinics in the us today. these diseases are also some of the most painful eye disorders. two important areas for research on the cornea are 1) to explore and understand the molecular basis of corneal transparency and 2) to analyze the molecular nature of corneal inflammation and wound healing. we have developed a new clinical device to understand molecular changes that occur in the lens, called dynamic light scattering (dls) device. studies have shown its potential in the detection of the earliest changes occurring in the cataract, and have also shown good test retest reproducibility of the system. we now would like to apply this technique to study changes that occur in corneal opacification. in this pilot project, we would like to study the normal cornea in young and older persons (volunteers) as well as cloudy, opaque corneas. this will allow us to determine if useful data can be obtained, and if so, lead to further studies in various corneal disorders caused by trauma, infections, and dystrophies, as well as those caused by systemic or inherited disorders.

Eligibility criteria:
inclusion criteria: individuals greater than or equal to 18 years of age. controls: control subjects must have normal, clear corneas as determined by slit lamp biomicroscopy and central corneal thickness less than 0.55 mm centrally. patients: patients with corneal clouding and opacification. exclusion criteria: to be eligible, participants must not satisfy the criterion below: individuals who cannot cooperate or keep still for the dls measurements.

Keywords: normal volunteers dynamic light scattering (dls) corneal opacities cornea transparency vision
pramlintide and fiasp closed-loop with a simple meal announcement

Conditions: Type 1 Diabetes Mellitus

Summary: the aim of this pilot study is to generate preliminary data of (i) fiasp-plus-pramlintide closed-loop system with a simple meal announcement, compared to (ii) fiasp-alone closed-loop system with full carbohydrate counting, in preparation for an outpatient study over two weeks


Eligibility criteria:
inclusion criteria: 1. males and females ≥ 12 years of age. 2. clinical diagnosis of type 1 diabetes for at least 12 months according to the diabetes canada clinical practice guidelines expert committee diagnostic criteria. 3. the diagnosis of type 1 diabetes is based on the investigator's judgment; c peptide level and antibody determinations are not needed. 4. insulin pump therapy for at least 6 months. 5. hba1c ≤ 12%. exclusion criteria: 1. current or ≤ 1 month use of other antihyperglycemic agents (sglt2 (sodium-glucose cotransporter-2), glp-1 (glucagon-like peptide 1), metformin, acarbose, etc....). 2. current use of glucocorticoid medication. 3. use of medication that alters gastrointestinal motility. 4. planned or ongoing pregnancy. 5. breastfeeding individuals. 6. severe hypoglycemic episode within one month of admission. 7. severe diabetes keto-acidosis episode within one month of admission. 8. clinically significant nephropathy, neuropathy or retinopathy as judged by the investigator. 9. recent (\< 6 months) acute macrovascular event e.g. acute coronary syndrome or cardiac surgery. 10. known hypersensitivity to any of the study drugs or their excipients. 11. individuals with hypoglycemia unawareness. 12. individuals with confirmed gastroparesis. 13. other serious medical illness likely to interfere with study participation or with the ability to complete the trial by the judgment of the investigator. 14. failure to comply with team's recommendations (e.g. not willing to eat meals/snacks, not willing to change pump parameters, etc.). study discontinuation/withdrawal 1. failure to comply with the protocol. 2. pregnancy. 3. after an event which the pi believes it is not in the best interest for the patient to continue the trial.

Keywords: type 1 diabetes artificial pancreas pramlintide closed-loop
reduction and fixation of metatarsal neck fracture by metaizeau's technique

Conditions: Displaced Metatarsal Neck Fracture

Summary: metatarsal fractures represent 3-7% of all fractures of the body and 35% of fractures of the foot and have a rate of 75 new cases per 10,000 persons per year. the goal of treatment is to achieve a correct reduction of fracture, to avoid prolonged disability and preservation of both soft tissues and bony alignment. metaizeau's technique in these fracture of the metatarsal bone respects the soft tissues surrounding the fracture and the periosteum at the fracture site.

metatarsal fractures represent 3-7% of all fractures of the body and 35% of fractures of the foot and have a rate of 75 new cases per 10,000 persons per year. metatarsal fractures have been considered of little importance by many authors over the years, and have received little attention. that is why little literature about operative management of metatarsal fractures can be found (apart from the first and fifth metatarsal bones). generally, these are non-displaced fractures. when these fractures show some displacement, reasonable alignment must be obtained because the metatarsals' capability for remodelling is extensive but not infinite. displaced metatarsal neck fractures are usually treated by means of retrograde kirschner wires, which generally requires an open reduction at the fracture site due to the difficulty of reducing the metatarsal head. metaizeau's technique can be applied to reduce the displaced metatarsal head distally from the fracture in an easier way and to keep the fracture site closed, as compared with retrograde kirschner wires method . open reduction was unnecessary in all cases. this technique permitted correct control of the distal fracture fragment, obtained good reduction of the metatarsal heads without opening the fracture site, and with no lesion of the capsuloligamentous complex of metatarsophalangeal joint. metaizeau's technique is a valid alternative to retrograde method. the goal of treatment is to achieve a correct reduction of fracture, to avoid prolonged disability and preservation of both soft tissues and bony alignment. metaizeau's technique in these fracture of the metatarsal bone respects the soft tissues surrounding the fracture and the periosteum at the fracture site.

Eligibility criteria:
inclusion criteria: * adult patient with displaced fracture neck of the 2nd, 3rd or 4th metatarsal exclusion criteria: * poly_traumatized patient . * patient with fracture first and fifth metatarsal bone . * fracture shaft metatarsal bone , first mb, fifth mb. * open fractures of the foot . * intraarticular fracture of metatarsals . * lisfranc fracture . * segmental fracture of the metatarsals
results of coronary angiography rafter cabg: comparison between no-touch and conventional vein graft

Conditions: Bypass Graft Stenosis

Summary: coronary artery disease is one of the biggest health issue worldwide: it is estimated that cardiovascular diseases cause around 45% of all death in sweden and in the west world. the treatment, in a large part of the patients, implicates a so called bypass-operation, that consists in to connect new vascular conduits (grafts) beyond the narrowed coronary vessels to improve the blood supply to the heart. one of the graft that is commonly used is the saphenous vein from the leg. the disadvantage of the saphenous vein graft is the predisposition to early obstruction. the international literature shows the following grades of occlusion: 15% in the first year and 40% after 10 years. at the cardio-thoracic clinic of the university hospital of örebro has been developed a new method to harvest the saphenous vein together with the surrounding fat-tissue. this technique, called no-touch technique, has the advantage to reduce the damages to the vein during the harvesting, showing a substantially reduced risk for future occlusion (5% after 18 months and 10% after 8,5 years). 2020-05-20 2020-11-16 project created in: fou region örebro län resultat av koronarangiografi hos patienter som tidigare cabg opererats project number : 274418 created by: gabriele ferrari, 2020-05-20 last revised by: gabriele ferrari, 2020-11-16 ongoing the aim of the phd project is to evaluate the results of the no-touch technique in compare to the conventional technique for the venous graft harvesting. the focus of the study is to analyze all the operated patients in our clinic who underwent a post-operative coronary angiography do to angina pectoris (heart pain). one will compare the patency rate, the rate of mace (major adverse cardiac events) and the quality of life in the two groups (no-touch vs. conventional). this study is the first and the only one in the world that will examine the long-term angiographic results of the no-touch technique in patients that had angina pectoris after the operation.


Eligibility criteria:
inclusion criteria: * angina after cabg requiring diagnostic coronary angiography * cabg operation between 1992 and june 30th 2020 * coronary angiography between 2006 and june 30th 2020 exclusion criteria: * coronary angiography within 30 days from the cabg operation date

Keywords: vein graft no-touch angina coronary angiography graft patency
lux-breast 1: bibw 2992 (afatinib) in her2-positive metastatic breast cancer patients after one prior herceptin treatment

Conditions: Breast Neoplasms

Summary: to investigate the efficacy and safety of bibw 2992 in combination with vinorelbine i.v. chemotherapy as treatment in patients with her2-overexpressing, metastatic breast cancer, who failed one prior trastuzumab (herceptin®) treatment


Eligibility criteria:
inclusion criteria: * histologically confirmed diagnosis of her2-overexpression breast cancer * stage iv metastatic disease * must have progressed on one prior trastuzumab treatment * no more than one prior trastuzumab based therapy regimen (either adjuvant or first-line) * must have received anthracycline and/or taxane based chemotherapy for adjuvant treatment of breast cancer or first-line treatment of metastatic breast cancer * must have (archived) tumour tissue sample available for central re-assessment of her2-status * at least one measurable lesion according to recist 1.1. * eastern cooperative oncology group (ecog) score of 0 or 1 . exclusion criteria: * prior treatment with epidermal growth factor receptor/human epidermal growth factor receptor(egfr/her2)-targeted small molecules or antibodies other than trastuzumab * prior treatment with vinorelbine * known pre-existing interstitial lung disease * active brain metastases * history or presence of clinically relevant cardiovascular abnormalities such as uncontrolled hypertension, congestive heart failure nyha classification of 3, unstable angina or poorly controlled arrhythmia. myocardial infarction within 6 months prior to randomisation. * cardiac left ventricular function with resting ejection fraction of less than 50%. * patients unable to comply with the protocol. * any contraindications for therapy with vinorelbine or trastuzumab. * known hypersensitivity to bibw 2992 or the excipients of any of the trial drugs. * use of any investigational drug within 4 weeks of randomisation. * inadequate hepatic, renal and haematologic organ function
testing multiple behavioral science strategies to increase flu-shot rates at a large retail pharmacy

Conditions: Influenza, Human

Summary: this research aims to identify which behavioral science strategies are most effective at increasing flu vaccination rates overall and based on patients' individual characteristics. past behavioral science interventions have shown promise in increasing flu vaccinations. for example, successful interventions have encouraged people to make concrete plans for when they will get a flu vaccination, sent automated calls or text messages reminding patients to get a flu vaccination , or provided financial incentives for getting vaccinated. although these results are promising, these studies have been conducted in isolation on different populations, which makes it difficult to compare their interventions' effectiveness or to have enough power to reliably detect differing responses to interventions based on individual characteristics. this research will simultaneously test 22 different sms interventions to increase flu vaccinations compared to a holdout control condition in a "mega-study" and apply machine learning to identify which interventions work best for whom. the interventions are designed by behavioral science experts from the behavior change for good initiative (bcfg), penn medicine nudge unit (pmnu), and geisinger behavioral insights team (bit). customers of a large retail pharmacy who received a flu shot from the pharmacy last year and receive sms notifications will be included in this study. we expect this to include approximately 1.2 million participants. the specific aims of this research are to identify (1) which behavioral science strategies effectively increase flu vaccination rates overall, and (2) which strategies are most effective for different subgroups (e.g., based on age, gender, race).


Eligibility criteria:
inclusion criteria: 1. have agreed to receive sms messages from the pharmacy 2. received a flu shot from the pharmacy in the 2019-2020 flu season, as documented in their pharmacy records. exclusion criteria: -

Keywords: influenza vaccination behavioral science interventions vaccination promotion